Skip to content

SankoreAfrican research intelligence

Countries
Institutions
Fields
Rankings
Compare

Search institutions, scholars, countries and publications

Sankore

Named after the University of Sankore in Timbuktu — one of the world’s oldest centres of learning. Every figure here is computed from work-level records in our own graph, never copied from a source’s summary count.

Built from

OpenAlex — works, authorships, subject classification
ROR — institutional identity
ORCID — researcher identity
Crossref — publisher confirmation

Browse

Countries
Institutions
Fields
Rankings
What we cover

Coverage is partial and says so. A country appears with its research output only once its works have been swept; until then the portal shows whatever the graph happens to hold for it and labels it as exactly that.

Michal Juraska · Sankore

Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa

Michal Juraska

ORCID, self-asserted

ORCID 0000-0002-0920-2915

This profile carries an ORCID the researcher published on their own record — the strongest evidence available short of a human confirming it.

Publications

20

Citations

387

h-index

11

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

11

Read this before using these figures

The graph holds no coverage record for this country.

Publications

3 works in the graph, newest first.

Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial
2024The Lancet Infectious DiseasesJournalOpen accessFirst authorCorresponding17 citations10.1016/s1473-3099(24)00179-8
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial
2023The Lancet Respiratory MedicineJournalOpen access25 citations10.1016/s2213-2600(23)00263-1
Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study
2023EClinicalMedicineJournalOpen access11 citations10.1016/j.eclinm.2023.102168